Stay updated with breaking news from Project lucy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alert: Magic Mushrooms: The New Weed Stocks? More on: Image source: Getty Images This title would have been far more scandalous 10 years ago. But it’s 2020 and nothing is surprising anymore. In recent weeks a new sector has emerged that could be as promising (and perhaps as lucrative) as legal marijuana: magic mushroom medical treatments. Public perception about these substances could be on the verge of shifting ads the medical community uncovers their benefits. If you’re an investor looking for the next big hype cycle before it’s too late, here’s what you need to know. Magic mushroom science ....
MindMed Announces $50 Million Bought Deal Public Offering THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES . Mind Medicine Inc. the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. pursuant to which the Lead Underwriter has agreed, on … /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the “Lead Underwriter”) pursuant to which the Lea ....
Share this article Provides Clinical Development Update on 18-MC Based on positive pre-IND meeting with U.S. Food and Drug Administration (FDA), MindMed is now prepared to open an Investigational New Drug (IND) in August 2021 with a Phase 2b clinical trial for LSD assisted therapy in anxiety MindMed continues dose escalation of 18-MC in Phase I SAD/MAD; Meeting confirmed with FDA NEW YORK, Dec. 14, 2020 /PRNewswire/ MindMed (NEO: MMED,OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder. ....